Biologika bei chronisch-entzündlichen Darmerkrankungen

Chronisch-entzündliche Darmerkrankungen gehören zu den häufigen immunvermittelten Krankheiten. Sie bedeuten für Betroffene Schmerzen und eine erhebliche Einschränkung ihrer Lebensqualität. In den letzten Jahren hat sich die Palette an verfügbaren Therapieoptionen erheblich erweitert. Dieser Artikel gibt einen Überblick über die aktuell verfügbaren Biologika-Therapien und worauf dabei zu achten ist.

Kernaussagen

• Biologika stellen einen unverzichtbaren Baustein in der Behandlung chronisch entzündlicher Darmerkrankungen dar.

• Die Wahl des Biologikums erfolgt individuell (z. B. je nach Krankheitslast, Präferenz, Vortherapien), eine festgelegte Therapiesequenz existiert nicht.

• Biologika sind sicher. Es gibt nur wenige Kontraindikationen für ihren Einsatz (vor allem unbehandelte Infektionen, Multiple Sklerose bei Anti-TNF-AK).

• Biologika können (und sollen) während Schwangerschaft und Stillzeit verabreicht werden.

• Kombinationstherapien sind teilweise bereits etabliert, mit neuen Möglichkeiten der Kombinationstherapie ist zu rechnen.

• Die neuen Anti-IL-23-AK zeichnen sich durch eine gute Wirkung in Kombination mit einem hervorragenden Sicherheitsprofil aus.

• Proaktives therapeutisches Drug Monitoring bei Anti-TNF-AK erhöht die Wirksamkeit und verhindert Wirkverlust.

Schlüsselwörter

chronisch entzündliche Darmerkrankungen - Morbus Crohn - Colitis ulcerosa - Therapie - Biologika

Publication History

Article published online:
29 September 2025

• Literatur

• 1 Farrag K, Ulrich-Rückert S, Schulz F. et al. Chronisch-entzündliche Darmerkrankungen: Status quo und was die Zukunft bringen kann. Dtsch Arztebl Ausg A 2023; 120: A1219-1223
• 2 Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA 2023; 330: 951-965
• 3 Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet 2024; 403: 1177-1191
• 4 Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 2019; 20: 970-979
• 5 Turner D, Ricciuto A, Lewis A. et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160: 1570-1583
• 6 Kucharzik T, Ellul P, Greuter T. et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021; 15: 879-913
• 7 Noor NM, Lee JC, Bond S. et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9: 415-427
• 8 Lichtenstein L, Ron Y, Kivity S. et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis 2015; 9: 806-815
• 9 Rivière P, Suen CLW, Chaparro M. et al. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol 2024; 9: 251-262
• 10 Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF-α Blockers. Curr Neurol Neurosci Rep 2017; 17: 36
• 11 Hanauer SB, Feagan BG, Lichtenstein GR. et al. Maintenance infliximab in Crohn’s disease: The ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
• 12 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
• 13 Sandborn WJ, Hanauer SB, Rutgeerts P. et al. Adalimumab for maintenance treatment of Crohn’s disease: Results of the CLASSIC II trial. Gut 2007; 56: 1232-1239
• 14 Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y) 2013; 9: 317-320
• 15 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.e1
• 16 Brun MK, Gehin JE, Bjørlykke KH. et al. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials. Lancet Rheumatol 2024; 6: e226-e236
• 17 Chanchlani N, Lin S, Bewshea C. et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn’s disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol 2024; 9: 521-538
• 18 Peyrin-Biroulet L, Chapman JC, Colombel J-F. et al. Risankizumab versus Ustekinumab for moderate-to-severe Crohn’s disease. N Engl J Med 2024; 391: 213-223
• 19 Danese S, Panaccione R, Feagan BG. et al. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol 2024; 9: 133-146
• 20 Feagan BG, Sandborn WJ, Gasink C. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375: 1946-1960
• 21 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381: 1201-1214
• 22 D’Haens G, Panaccione R, Baert F. et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 2022; 399: 2015-2030
• 23 Ferrante M, Panaccione R, Baert F. et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022; 399: 2031-2046
• 24 Louis E, Schreiber S, Panaccione R. et al. Mirikizuma. JAMA 2024; 332: 881
• 25 D’Haens G, Dubinsky M, Kobayashi T. et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2023; 388: 2444-2455
• 26 Ferrante M, D’Haens G, Jairath V. et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 2024; 404: 2423-2436
• 27 Panaccione R, Feagan BG, Afzali A. et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn’s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. Lancet 2025; 406: 358-375
• 28 Rubin DT, Allegretti JR, Panés J. et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet 2025; 405: 33-49
• 29 Hart A, Panaccione R, Steinwurz F. et al. Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study. Gastroenterology 2025; 169: 308-325
• 30 Sandborn WJ, Feagan BG, Rutgeerts P. et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
• 31 Feagan BG, Rutgeerts P, Sands BE. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
• 32 Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease?. Therap Adv Gastroenterol 2023; 16: 1-12
• 33 Colombel JF, Sandborn WJ, Reinisch W. et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
• 34 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3
• 35 Feagan BG, Sands BE, Sandborn WJ. et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol 2023; 8: 307-320
• 36 Nielsen OH, Gubatan JM, Kolho KL. et al. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. Lancet 2024; 403: 1291-1303
• 37 Greuter T, Vavricka S, König AO. et al. Malignancies in inflammatory bowel disease. Digestion 2020; 101: 136-145
• 38 Laredo V, García-Mateo S, Martínez-Domínguez SJ. et al. Risk of cancer in patients with inflammatory bowel diseases and keys for patient management. Cancers (Basel) 2023; 15: 871
• 39 Kotlyar DS, Osterman MT, Diamond RH. et al. A systematic review of factors that contribute to hepatosplenic t-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.e1
• 40 Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol 2024; 22: 499-512.e6